NAL ER
NAL03-202
Phase 2 small_molecule active
Quick answer
NAL ER for Idiopathic Pulmonary Fibrosis is a Phase 2 program (small_molecule) at Trevi Therapeutics with 3 ClinicalTrials.gov record(s).
Program details
- Company
- Trevi Therapeutics
- Indication
- Idiopathic Pulmonary Fibrosis
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- active